Atossa Inks Deal for MASCT System; Buys Assets of Intraductal Dx, Therapy Firm | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics disclosed in a regulatory filing that it has entered into a co-exclusive marketing deal for the MASCT System and acquired the assets of intraductal diagnostic and therapeutic firm Acueity Healthcare.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.